Isomorphic Labs
Sergei Yakneen has a diverse work experience spanning various industries and roles. Sergei is currently working as the Chief Technology Officer at Isomorphic Labs, where they are responsible for leading all aspects of company computational Research and Development. Prior to this, Sergei held the same role at SOPHiA GENETICS, where they led the development and operation of cutting-edge products in the precision-medicine space. Sergei also has experience in research and technical program management roles at EMBL and the Ontario Institute for Cancer Research. Sergei's previous experience includes working as a Software Development Manager at Amazon.com and holding leadership positions in software engineering and development teams at BPS Resolver Inc., BPS, MapInfo, CIBC, and Manulife Financial.
Sergei Yakneen completed their education as follows:
- 2016-2019: Sergei earned a Doctor of Philosophy (PhD) in Computer Science from Heidelberg University.
- 1998-2004: Sergei obtained an Honours Bachelor of Science degree in Computer Science and Mathematics from the University of Toronto.
- 1994-1998: Sergei received a High School Diploma from Harbord Collegiate Institute.
Additionally, Sergei has several certifications in various fields such as differential equations, statistical methods of gene mapping, scalable machine learning, bioinformatics, virology, biostatistics, systems biology, neuroscience, and more. Sergei also obtained a Project Management Professional (PMP) certification from PMI.
This person is not in any offices
Isomorphic Labs
7 followers
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.